Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma.

Shields BD, Koss B, Taylor EM, Storey AJ, West KL, Byrum SD, Mackintosh SG, Edmondson R, Mahmoud F, Shalin SC, Tackett AJ.

Cancer Res. 2019 Mar 15;79(6):1113-1123. doi: 10.1158/0008-5472.CAN-18-1722. Epub 2019 Jan 23.

PMID:
30674537
2.

Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer.

Quaranta V, Rainer C, Nielsen SR, Raymant ML, Ahmed MS, Engle DD, Taylor A, Murray T, Campbell F, Palmer DH, Tuveson DA, Mielgo A, Schmid MC.

Cancer Res. 2018 Aug 1;78(15):4253-4269. doi: 10.1158/0008-5472.CAN-17-3876. Epub 2018 May 22.

3.

Inhibition of Rspo-Lgr4 Facilitates Checkpoint Blockade Therapy by Switching Macrophage Polarization.

Tan B, Shi X, Zhang J, Qin J, Zhang N, Ren H, Qian M, Siwko S, Carmon K, Liu Q, Han H, Du B, Liu M.

Cancer Res. 2018 Sep 1;78(17):4929-4942. doi: 10.1158/0008-5472.CAN-18-0152. Epub 2018 Jul 2.

PMID:
29967265
4.

An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade.

Vuong L, Kouverianou E, Rooney CM, McHugh BJ, Howie SEM, Gregory CD, Forbes SJ, Henderson NC, Zetterberg FR, Nilsson UJ, Leffler H, Ford P, Pedersen A, Gravelle L, Tantawi S, Schambye H, Sethi T, MacKinnon AC.

Cancer Res. 2019 Apr 1;79(7):1480-1492. doi: 10.1158/0008-5472.CAN-18-2244. Epub 2019 Jan 23.

PMID:
30674531
5.

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

Mahoney KM, Freeman GJ, McDermott DF.

Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Review.

6.

Indicators of responsiveness to immune checkpoint inhibitors.

Shields BD, Mahmoud F, Taylor EM, Byrum SD, Sengupta D, Koss B, Baldini G, Ransom S, Cline K, Mackintosh SG, Edmondson RD, Shalin S, Tackett AJ.

Sci Rep. 2017 Apr 11;7(1):807. doi: 10.1038/s41598-017-01000-2.

7.

CD4+ T-cell-Mediated Rejection of MHC Class II-Positive Tumor Cells Is Dependent on Antigen Secretion and Indirect Presentation on Host APCs.

Haabeth OAW, Fauskanger M, Manzke M, Lundin KU, Corthay A, Bogen B, Tveita AA.

Cancer Res. 2018 Aug 15;78(16):4573-4585. doi: 10.1158/0008-5472.CAN-17-2426. Epub 2018 May 11.

PMID:
29752262
8.

Sialic Acid Blockade Suppresses Tumor Growth by Enhancing T-cell-Mediated Tumor Immunity.

Büll C, Boltje TJ, Balneger N, Weischer SM, Wassink M, van Gemst JJ, Bloemendal VR, Boon L, van der Vlag J, Heise T, den Brok MH, Adema GJ.

Cancer Res. 2018 Jul 1;78(13):3574-3588. doi: 10.1158/0008-5472.CAN-17-3376. Epub 2018 Apr 27.

PMID:
29703719
9.

Adhesion of lymphocytes to bladder cancer cells: the role of the alpha(E)beta(7) integrin.

Cresswell J, Wong WK, Henry MJ, Robertson H, Neal DE, Kirby JA.

Cancer Immunol Immunother. 2002 Nov;51(9):483-91. Epub 2002 Aug 9.

PMID:
12357319
10.

Inhaled TLR9 Agonist Renders Lung Tumors Permissive to PD-1 Blockade by Promoting Optimal CD4+ and CD8+ T-cell Interplay.

Gallotta M, Assi H, Degagné É, Kannan SK, Coffman RL, Guiducci C.

Cancer Res. 2018 Sep 1;78(17):4943-4956. doi: 10.1158/0008-5472.CAN-18-0729. Epub 2018 Jun 26.

PMID:
29945961
11.

T cell adhesion and cytolysis of pancreatic cancer cells: a role for E-cadherin in immunotherapy?

French JJ, Cresswell J, Wong WK, Seymour K, Charnley RM, Kirby JA.

Br J Cancer. 2002 Oct 21;87(9):1034-41.

12.

CD103+ Cell Growth Factor Flt3L Enhances the Efficacy of Immune Checkpoint Blockades in Murine Glioblastoma Model.

Miao X, Chen Y, Hao K, Zheng M, Chen B, Li K, Wang Y, Zhang W, Zhang Y, Mou X, Jiang S, Wang Z.

Oncol Res. 2018 Mar 5;26(2):173-182. doi: 10.3727/096504017X14841698396865. Epub 2017 Jan 20.

PMID:
28109087
13.

Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma.

Elia AR, Caputo S, Bellone M.

Front Immunol. 2018 Jul 31;9:1786. doi: 10.3389/fimmu.2018.01786. eCollection 2018. Review.

14.

Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.

Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S, Casanova-Acebes M, Khudoynazarova M, Agudo J, Tung N, Chakarov S, Rivera C, Hogstad B, Bosenberg M, Hashimoto D, Gnjatic S, Bhardwaj N, Palucka AK, Brown BD, Brody J, Ginhoux F, Merad M.

Immunity. 2016 Apr 19;44(4):924-38. doi: 10.1016/j.immuni.2016.03.012.

15.

Targeting USP7 Identifies a Metastasis-Competent State within Bone Marrow-Resident Melanoma CTCs.

Vishnoi M, Boral D, Liu H, Sprouse ML, Yin W, Goswami-Sewell D, Tetzlaff MT, Davies MA, Oliva ICG, Marchetti D.

Cancer Res. 2018 Sep 15;78(18):5349-5362. doi: 10.1158/0008-5472.CAN-18-0644. Epub 2018 Jul 19.

PMID:
30026332
16.

Paclitaxel Reduces Tumor Growth by Reprogramming Tumor-Associated Macrophages to an M1 Profile in a TLR4-Dependent Manner.

Wanderley CW, Colón DF, Luiz JPM, Oliveira FF, Viacava PR, Leite CA, Pereira JA, Silva CM, Silva CR, Silva RL, Speck-Hernandez CA, Mota JM, Alves-Filho JC, Lima-Junior RC, Cunha TM, Cunha FQ.

Cancer Res. 2018 Oct 15;78(20):5891-5900. doi: 10.1158/0008-5472.CAN-17-3480. Epub 2018 Aug 13.

PMID:
30104241
17.

An engineered PD-1-based and MMP-2/9-oriented fusion protein exerts potent antitumor effects against melanoma.

Wei M, Liu X, Cao C, Yang J, Lv Y, Huang J, Wang Y, Qin Y.

BMB Rep. 2018 Nov;51(11):572-577.

18.

Systemic treatments for metastatic cutaneous melanoma.

Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S.

Cochrane Database Syst Rev. 2018 Feb 6;2:CD011123. doi: 10.1002/14651858.CD011123.pub2. Review.

PMID:
29405038
19.

Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4+Foxp3- Cell-Mediated Modulation of CD103+ Dendritic Cells.

Beavis PA, Henderson MA, Giuffrida L, Davenport AJ, Petley EV, House IG, Lai J, Sek K, Milenkovski N, John LB, Mardiana S, Slaney CY, Trapani JA, Loi S, Kershaw MH, Haynes NM, Darcy PK.

Cancer Immunol Res. 2018 Sep;6(9):1069-1081. doi: 10.1158/2326-6066.CIR-18-0291. Epub 2018 Jul 17.

PMID:
30018045
20.

Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.

Mahvi DA, Meyers JV, Tatar AJ, Contreras A, Suresh M, Leverson GE, Sen S, Cho CS.

J Immunother. 2015 Feb-Mar;38(2):54-61. doi: 10.1097/CJI.0000000000000064.

Supplemental Content

Support Center